Dow Jones received a payment from EQS/DGAP to publish this press release.
EQS-News / 09/09/2017 / 01:19 UTC+8
*?Immediate Release? 9 September, 2017*
*Yestar Healthcare Holdings Company Limited
(Stock Code: 2393.HK)*
*Grand Opening of "Shanghai Zhongke Runda Precision Medical Laboratory",
which is Collaboratively Launched by Yestar,* *Chinese Academy of Sciences
and
Runda Medical
Marks the Milestone of Yestar Forging Ahead Towards the Market of
Independent Third-Party Clinical Laboratory *
(Hong Kong - 9 September 2017) *Yestar Healthcare Holdings Company Limited
*("Yestar" or the "Company" together with its subsidiaries, the "Group",
stock code: 2393.HK) is pleased to announce that the Group collaborates with
Shanghai Advanced Research Institute of Chinese Academy of Sciences
("Chinese Academy of Sciences") and Shanghai Runda Medical Science and
Technology Co., Ltd ("Runda Medical") to launch Shanghai Zhongke Runda
Precision Medical Laboratory ("Zhongke Runda"), an independent third-party
medical examination laboratory, had its grand opening ceremony in Shanghai
on 8 September 2017. Zhongke Runda carries the mission to become the
benchmark for precise medical examination centers in Shanghai and marks the
milestone of creating a leading integrated healthcare services platform for
the Group.
In light of the progressive reform of the medical and healthcare industry in
China, the categorized medical system and centralized testing of
regionalized healthcare have become the major driving forces, propelling the
demand for independent third-party clinical laboratories and market
development. Therefore, the Group allied with Chinese Academy of Sciences
and Runda Medical to launch Zhongke Runda, an independent third-party
clinical laboratory, in order to seize the opportunity and fill gaps in the
market. Zhongke Runda is located in the Zhejiang National Innovation
Demonstration Zone, Hongkou, Shanghai and imports the international standard
system with high quality, adopting the most advancing LIMS system in the
world and co-operates with elites in the medical testing field. Facilitated
with the leading automated testing equipment, Zhongke Runda is enabled to
accumulate massive sample and clinical information on precise medical
testing. Embroidered with these advantages, Zhongke Runda will strive to
earn clinical and scientific research projects and provide healthcare
institutions of each level with services such as medical examination,
pathology testing and research. Together with cloud data management
technology, Zhongke Runda will be able to offer a platform of standardized
data and contribute towards the healthcare management.
On the other hand, Zhongke Runda and Roche Diagnostics co-operated and built
three "Roche Model Lab". Adopting equipment with leading testing technology
and advanced management concepts for laboratories, they will jointly build
world's leading medical examination laboratories, featuring high quality and
automation. They are also the first healthcare institution in Shanghai to
employ equipment for after-treatment
Regarding the co-operation, *Mr. Wong Fatt Heng, General Manager of Roche
Diagnostic (China)*, commented, "Roche Diagnostics has always valued the
co-operation with independent third-party clinical laboratories in China. We
wish to enhance the testing quality and efficiency of laboratories while
bringing the best diagnostic technology and testing projects with valuable
clinical values to China. It is also our goal to expand the coverage to more
mid-to-small sized and community hospitals and serve patients with
individualized healthcare management. Today, we are very delighted to
collaboratively build three "Roche Model Lab" with Zhongke Runda, featuring
functions such as biochemical immunoassay, molecular testing and pathology.
This collaboration will allow us to provide the market with more
comprehensive solutions for laboratories and support the elevation of
general standard of the Chinese laboratories, as well as speeding up its
convergence with the world."
*Mr. James Hartono, the Chairman of Yestar Healthcare*, stated, "Being one
of the leading distributors of the high margin consumables and equipment in
China, Yestar has been strengthening its current foundation of In-Vitro
Diagnostic segment while continuously exploring new businesses that form
synergies with its diagnostic segment. According to Industry Whitepaper and
analyst report, IMS analysis, Industry Experts Interview, China Independent
Clinical Laboratory (ICL) market forecast will keep its 22% CARG growth from
Year 2015 to Year 2025, reaching RMB 74 billion, due to further
implementation of the Chinese goverment's medical reforms initiatives. As
the supplement for the current healthcare sector, independent third-party
clinical laboratories aid to enhance the overall testing standard. Zhongke
Runda as Yestar's first investment in the field of independent third-party
clinical laboratory projects (currently owns 39% equity interest in Zhongke
Runda), has received great support from parties such as Shanghai Government
and Roche Diagnostic. Zhongke Runda has also brought in the most advanced
system of automated operation lines and automated equipment for testing, for
providing patients with high quality, efficient and convenient testing
services and setting the highest standard. This will enable Zhongke Runda to
contribute through driving the reform of the medical and hygiene industry in
China and promote the health development of the public."
- End -
*About Yestar Healthcare Holdings Company Limited*
Yestar Healthcare Holdings Company Limited (formerly known as Yestar
International Holdings Company Limited) is the largest distributor of
Fujifilm products in the PRC and have been transformed itself into a high
margin medical consumables manufacturer and distributor in the PRC since
2014. Targeting the booming domestic healthcare industry, the core business
of the Group focuses on high margin and fast-moving healthcare consumables
namely, IVD products and medical imaging products.
*About Shanghai Advanced Research Institute, Chinese Academy of Sciences*
Shanghai Advanced Research Institute, Chinese Academy of Sciences ("Chinese
Academy of Sciences") is the highest academic institute in natural science,
the most prestigious science and technology consultancy and an integrated
research and development center for natural science and high technology in
the PRC. The institutes assembles elites and high-tech equipments, providing
technical support for Zhongke Runda.
*About Shanghai Runda MedicalScience and Technology Co., Ltd*
Shanghai Runda MedicalScience and Technology Co., Ltd("Runda Medical")
(Stock code: 603108)is a provider of integrated solutions for medical
laboratories. Runda Medical has become one of the leading companies in both
domestic and overseas IVD product circulation and service industry.
This press release is issued by DLK Advisory Limited on behalf of *Yestar
Healthcare Holdings Company Limited*.
For enquiries, please contact:
*DLK Advisory *
Tel: +852 2857 7101
Fax: +852 2857 7103
Document: http://n.eqs.com/c/fncls.ssp?u=RKQHWRUWHJ [1]
Document title: [2393.HK]Press Release_20170909
09/09/2017 Dissemination of a Financial Press Release, transmitted by EQS
Group.
The issuer is solely responsible for the content of this announcement.
Media archive at www.todayir.com
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e3bb106b9b3a741d8a4f99b349132b98&application_id=608185&site_id=vwd&application_name=news
(END) Dow Jones Newswires
September 08, 2017 13:20 ET (17:20 GMT)
